课题基金 / 基金详情

SPORE in Endometrial Cancer

SPORE in Endometrial Cancer
子宫内膜癌中的孢子
批准号:
8119020
负责人:
David G Mutch
金额:
$47.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-18 至 2014-08-31
关键词:

项目摘要

项目成果

David G Mutch的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This Specialized Program of Research Excellence (SPORE) in Endometrial Cancer is submitted by Washington University in St. Louis, the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine. It includes four research projects, three supportive cores, and research and career development programs. This proposal brings together basic and applied investigators to conduct innovative and diverse translational investigations aimed at preventing, diagnosing and treating endometrial cancer. The four projects in our application have been carefully designed to have significant potential to change clinical practice within five years. Project 1: FGFR2 as therapeutic target in endometrial cancer Project 2: Methylation markers for prognosis in endometrioid endometrial cancers Project 3: Identifying inherited endometrial cancer & the environmental and genetic factors contributing to somatic loss of mismatch repair Project 4: Novel effectors of ERK signaling and their potential roles in the treatment of endometrial cancer The four projects represent carefully chosen marriages between selected endometrial cancer research priorities and the strengths of Washington University and our collaborators. The critical objectives that we have chosen to focus on are to: 1) improve the treatment of patients with persistent or recurrent endometrial cancer using a molecularly targeted therapy and determine if upfront adjuvant biologic therapies hold promise for improving outcomes in the general endometrial cancer population; 2) develop prognostic markers to help guide the treatment of women with the most common form of uterine tumors, endometrioid endometrial cancer; 3) optimize detection of those women with inherited forms of endometrial cancer so they and their at-risk family members can receive risk-appropriate (intensified) cancer surveillance; and 4) elucidate the role novel effectors of ERK signaling play in uterine cancer and assess opportunities for targeting these in the treatment of endometrial cancers. Three Cores will support these projects: Administration, Tissue & Pathology, and Biostatistics. The Developmental Research Program will support a pathway for continued identification and support of diverse research that could replace or improve current projects, and a Career Development Program will recruit and support candidates committed to training in translational research in endometrial cancer.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Lineage-specific biomarkers predict response to FGFR inhibition.
谱系特异性生物标志物预测对 FGFR 抑制的反应。
DOI: 10.1158/2159-8290.cd-12-0486
发表时间: 2012
期刊: Cancer discovery
影响因子: 28.2
作者: [Loch,DavidC, Pollock,PamelaM]
通讯作者: Pollock,PamelaM
DOI: 10.1002/0471250953.bi1010s40
发表时间: 2012-12
期刊: Current protocols in bioinformatics
影响因子: --
作者: [Zhou, Xin, Wang, Ting]
通讯作者: Wang, Ting
DOI: 10.1016/j.molmed.2011.01.012
发表时间: 2011-05
期刊: Trends in molecular medicine
影响因子: 13.6
作者: [Greulich H, Pollock PM]
通讯作者: Pollock PM
Career Enhancement Program
  • 批准号:
    10711642
  • 项目类别:
  • 资助金额:
    $10.95万
  • 财政年份:
    2023
  • 负责人:
    David G Mutch
  • 依托单位:
Project 2: Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
  • 批准号:
    10711637
  • 项目类别:
  • 资助金额:
    $40.86万
  • 财政年份:
    2023
  • 负责人:
    David G Mutch
  • 依托单位:
Administrative Core
  • 批准号:
    10711635
  • 项目类别:
  • 资助金额:
    $42.51万
  • 财政年份:
    2023
  • 负责人:
    David G Mutch
  • 依托单位:
海外基金